Ginkgo Bioworks Holdings Inc (NYSE: DNA) kicked off on Monday, up 10.46% from the previous trading day, before settling in for the closing price of $8.70. Over the past 52 weeks, DNA has traded in a range of $5.26-$75.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 104.75%. While this was happening, its average annual earnings per share was recorded 45.22%. With a float of $36.32 million, this company’s outstanding shares have now reached $41.37 million.
The extent of productivity of a business whose workforce counts for 1218 workers is very important to gauge. In terms of profitability, gross margin is 63.73%, operating margin of -271.32%, and the pretax margin is -298.94%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 33.34%, while institutional ownership is 47.97%. The most recent insider transaction that took place on Dec 02 ’24, was worth 871. Before that another transaction happened on Nov 29 ’24, when Company’s Officer proposed sale 99 for $8.40, making the entire transaction worth $832.
Ginkgo Bioworks Holdings Inc (DNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 45.22% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Take a look at Ginkgo Bioworks Holdings Inc’s (DNA) current performance indicators. Last quarter, stock had a quick ratio of 5.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.90, a number that is poised to hit -1.50 in the next quarter and is forecasted to reach -5.88 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
The latest stats from [Ginkgo Bioworks Holdings Inc, DNA] show that its last 5-days average volume of 0.95 million was inferior to 1.15 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 97.06%. Additionally, its Average True Range was 0.71.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 39.08%, which indicates a significant decrease from 88.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 124.91% in the past 14 days, which was higher than the 111.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.96, while its 200-day Moving Average is $21.50. Now, the first resistance to watch is $10.00. This is followed by the second major resistance level at $10.39. The third major resistance level sits at $11.05. If the price goes on to break the first support level at $8.95, it is likely to go to the next support level at $8.30. Assuming the price breaks the second support level, the third support level stands at $7.91.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
The company with the Market Capitalisation of 581.80 million has total of 57,479K Shares Outstanding. Its annual sales at the moment are 251,460 K in contrast with the sum of -892,870 K annual income. Company’s last quarter sales were recorded 89,050 K and last quarter income was -56,400 K.
